Disposition of 17842500 shares by Hhlr Advisors, Ltd. of BeiGene at 200.0 subject to Rule 16b-3
| BGNE Stock | USD 187.50 20.12 9.69% |
About 61% of BeiGene's investor base is looking to short. The analysis of the overall investor sentiment regarding BeiGene suggests that many traders are alarmed. The current market sentiment, together with BeiGene's historical and current headlines, can help investors time the market. In addition, many technical investors use BeiGene stock news signals to limit their universe of possible portfolio assets.
BeiGene |
Filed transaction by BeiGene 10 Percent Owner. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at insidermonkey.com
 |
BeiGene Fundamental Analysis
We analyze BeiGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeiGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeiGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
BeiGene is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
BeiGene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeiGene stock to make a market-neutral strategy. Peer analysis of BeiGene could also be used in its relative valuation, which is a method of valuing BeiGene by comparing valuation metrics with similar companies.
Peers
BeiGene Related Equities
| IMAB | I Mab | 0.95 | ||||
| KRYS | Krystal Biotech | 0.74 | ||||
| PCVX | Vaxcyte | 0.69 | ||||
| INCY | Incyte | 0.01 | ||||
| IMVT | Immunovant | 0.17 | ||||
| TVTX | Travere Therapeutics | 0.37 | ||||
| BMRN | Biomarin Pharmaceutical | 0.69 | ||||
| IONS | Ionis Pharmaceuticals | 0.71 | ||||
| AKRO | Akero Therapeutics | 0.95 | ||||
| BPMC | Blueprint Medicines | 0.96 | ||||
| APLS | Apellis Pharmaceuticals | 1.09 | ||||
| ASND | Ascendis Pharma | 2.08 | ||||
| ARWR | Arrowhead Pharmaceuticals | 4.97 | ||||
| LEGN | Legend Biotech | 8.96 |
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |